NASDAQ · XGN
Exagen Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for XGN: Nov 10, 2026
Exagen Inc. Common Stock is expected to report earnings on 11/10/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.19. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.19 | $-0.18 | $-0.20 | 2 |
| Dec 2026 | $-0.19 | $-0.18 | $-0.20 | 2 |
| Mar 2027 | $-0.18 | $-0.17 | $-0.19 | 2 |
| Jun 2027 | $-0.12 | $-0.11 | $-0.12 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · Zacks- The Motley Fool · Aug 11, 1:31 PM EDTExagen (XGN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 4, 3:04 PM EDTExagen Q2 Earnings Call HighlightsExagen (NASDAQ:XGN) reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even. Revenue for the quarter ended June 30 rose 16% year ov
- Zacks · Aug 4, 9:20 AM EDTExagen Inc. (XGN) Reports Q2 Loss, Beats Revenue EstimatesExagen (XGN) delivered earnings and revenue surprises of +31.58% and +10.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 28, 9:55 AM EDTHow Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- The Motley Fool · May 12, 2:16 PM EDTExagen (XGN) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 11, 1:09 PM EDTExagen Q1 Earnings Call HighlightsExagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter. The aut
- Zacks · May 11, 9:20 AM EDTExagen Inc. (XGN) Reports Q1 Loss, Beats Revenue EstimatesExagen (XGN) delivered earnings and revenue surprises of +29.17% and +4.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 5, 5:15 PM EDTAtriCure (ATRC) Reports Break-Even Earnings for Q1AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 28, 7:40 AM EDTZimmer Biomet (ZBH) Q1 Earnings and Revenues Top EstimatesZimmer (ZBH) delivered earnings and revenue surprises of +12.57% and +1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 10, 9:20 AM EDTExagen Inc. (XGN) Reports Q4 Loss, Beats Revenue EstimatesExagen (XGN) delivered earnings and revenue surprises of 0.00% and +1.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 9, 5:35 PM EDTMyomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue EstimatesMyomo (MYO) delivered earnings and revenue surprises of +5.88% and +11.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Feb 25, 7:25 PM ESTAgilent Technologies (A) Lags Q1 Earnings and Revenue EstimatesAgilent (A) delivered earnings and revenue surprises of -0.52% and -0.27%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Exagen Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.